Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Gastric Cancer | Research

A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis

Authors: Qiang Wang, Junbin Zhong, Qing Huang, Zhuanpeng Chen, Jianchang Wei, Fang Wei, Jie Cao

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Compared to conventional adenocarcinoma (CA), mucin-producing adenocarcinoma (MPA) is an uncommon histological subtype and is usually separated from other histological types and has been evaluated separately. The objective was to compare the clinicopathological characteristics and survivals of MPA with CA.

Methods

We retrospectively analyzed 1515 MPA patients in SEER database. Log-rank tests and KM survival curves were applied to determine the differences in overall survival (OS) and cancer specific survival (CSS) time.

Results

No significant differences were noted in OS and CSS time. The MPA patients who were treated with surgery and chemotherapy exhibited longer OS and CSS time periods than those without treatment. MPA patients treated with radiotherapy exhibited similar OS and CSS time with those without radiotherapy. MPA was not a prognostic factor of survival.

Conclusions

MPA was a rare histological type of gastric cancer. Patients with MPA exhibited similar prognosis with those with CA. Surgery and chemotherapy were effective treatments for patients with MPA.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. Acta Pathol Jpn. 1982;32:329–47.PubMed

Park JM, Jang YJ, Kim JH, Park SS, Park SH, Kim SJ, et al. Gastric cancer histology: clinicopathologic characteristics and prognostic value. J Surg Oncol. 2008;98(7):520–5. https://doi.org/10.1002/jso.21150.CrossRefPubMed

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. https://doi.org/10.1007/s10120-016-0622-4.CrossRef

Hamilton SR, Aaltonen LA. World health organization classifcation of tumours. Pathologyand genetics. Tumours of the digestive system. IARC: Lyon; 2000.

Yang XF, Yang L, Mao XY, Wu DY, Zhang SM, Xin Y. Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: acomparative study. World J Gastroenterol. 2004;10(5):750–4. https://doi.org/10.3748/wjg.v10.i5.750.CrossRefPubMedPubMedCentral

Wu CY, Yeh HZ, Shih RT, Chen GH. A clinicopathologic study of mucinous gastric carcinoma including multivariate analysis. Cancer. 1998;83(7):1312–8. https://doi.org/10.1002/(SICI)1097-0142(19981001)83:7<1312::AID-CNCR7>3.0.CO;2-K.CrossRefPubMed

Pozos-Ochoa LI, Lino-Silva LS, León-Takahashi AM, Salcedo-Hernández RA. Prognosis of sig-net ring cell carcinoma of the colon and rectum and their distinction of mucinous adenocarcinoma with signet ring cells. A Comparativestudy. Pathol Oncol Res. 2018;24:609–16.CrossRef

Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al. Clinicopathology and outcomes formucinous and signet ring colorectal adenocarcinoma: analysis from the national cancerdata base. Ann Surg Oncol. 2012;19:2814–21.CrossRef

10.

Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinicalpresentation. Ann Surg. 2009;250(6):878–87. https://doi.org/10.1097/SLA.0b013e3181b21c7b.CrossRefPubMed

11.

Yin C, Li D, Sun Z, Zhang T, Xu Y, Wang Z, et al. Clinicopathologic features and prognosis analysis of mucinous gastric carcinoma. Med Oncol. 2012;29(2):864–70. https://doi.org/10.1007/s12032-011-9825-z.CrossRefPubMed

12.

Yasuda K, Adachi Y, Shiraishi N, Yamaguchi K, Shiromizu A, Kitano S. Pathology and prognosis of mucinous gastric carcinoma. J Surg Oncol. 2001;76:272–7.CrossRef

13.

Isobe T, Hashimoto K, Kizaki J, Matono S, Murakami N. KinugasaT et al. Characteristics and prognosis ofmucinous gastric carcinoma. Mol Clin Oncol. 2015;3(1):44–50.CrossRef

14.

Adachi Y, Yasuda K, Inomata M, Shiraishi N, Kitano S. SugimachiK. Clinicopathologic study of early-stage mucinous gastric carcinoma. Cancer. 2001;91(4):698–703. https://doi.org/10.1002/1097-0142(20010215)91:4<698::AID-CNCR1054>3.0.CO;2-O.CrossRefPubMed

15.

Lin CL, Zhu GW, Huang YJ, Zheng W, Yang SG, Ye JX. Operable gastric adenocarcinoma with different histological subtypes: Cancer specifc survival in the United States. Saudi J Gastroenterol. 2020;26(1):46–52. https://doi.org/10.4103/sjg.SJG_406_19.CrossRefPubMed

16.

Zhang M, Zhu GY, Zhang HF, Gao HY, Han XF, Xue YW. Clinicopathologic characteristics and prognosis of mucinous gastric carcinoma. J Surg Oncol. 2010;102(1):64–7. https://doi.org/10.1002/jso.21533.CrossRefPubMed

17.

ISOBE T, HASHIMOTO K, KIZAKI J, MATONO S, MURAKAMI N, KINUGASA T, et al. Characteristics and prognosis of mucinous gastric carcinoma. MOLECULAR AND CLINICAL ONCOLOGY. 2015;3(1):44–50. https://doi.org/10.3892/mco.2014.447.CrossRef

18.

Yuan Y, Chen Z, Chen J, Huang W, Peng J, Ye J, et al. Mucinous gastric carcinoma: an update of clinicopathologic features and prognostic value from a retrospective study of clinical series. Int J Clin Exp Pathol. 2018;11(2):813–21.PubMedPubMedCentral

19.

Kim DY, Park YK, Joo JK, Ryu SY, Kim YJ, Kim SK, et al. Clinicopathological characteristics of signet ringcell carcinoma of the stomach. ANZ J Surg. 2004;74:1060–4.CrossRef

20.

Gronnier C, Messager M, Robb WB, Thiebot T, Louis D, Luc G, et al. Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma. Surgery. 2013;154(5):1093–9. https://doi.org/10.1016/j.surg.2013.05.020.CrossRefPubMed

21.

Jiang CG, Wang ZN, Sun Z, Liu FN, Yu M, Xu HM. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese monoinstitutional study. J Surg Oncol. 2011;103(7):700–3. https://doi.org/10.1002/jso.21878.CrossRefPubMed

22.

Chiu CT, Kuo CJ, Yeh TS, Hsu JT, Liu KH, Yeh CN, et al. Early signet ring cell gastric cancer. Dig Dis Sci. 2011;56(6):1749–56. https://doi.org/10.1007/s10620-010-1487-8.CrossRefPubMed

23.

Liu Z, Wu S, Gou S, Li Y, Wu H, Li Y. A Population-Based Study of the Incidence and Survival of Anorectal Gastrointestinal Stromal Tumor. Med Sci Monit. 2019;21(25):5408–17.CrossRef

24.

Wei J, Yang P, Huang Q, Chen Z, Zhang T, He F, et al. Proximal versus total gastrectomy for proximal gastric cancer: a surveillance, epidemiology, and end results program database analysis. Future Oncol. 2021;17(10):1185–95. https://doi.org/10.2217/fon-2020-1071.CrossRefPubMed

25.

Japanese Gastric Cancer Association. Japanese classification of gastriccarcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12. https://doi.org/10.1007/s10120-011-0041-5.CrossRef

26.

Liu K, Wan J, Bei Y, Chen X, Lu M. Prognostic impact of different histological types on gastric adenocarcinoma: a surveillance, epidemiology, and end results database analysis Pathol. Oncol Res. 2017;23(4):881–7. https://doi.org/10.1007/s12253-017-0198-2.CrossRef

27.

Zheng D, Cooke D. A survival comparison of mucin-producing adenocarcinoma of the esophagus to conventional adenocarcinoma after Esophagectomy. Am Surg. 2013;79(1):49–53. https://doi.org/10.1177/000313481307900128.CrossRefPubMed

Title: A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis
Authors: Qiang Wang
Junbin Zhong
Qing Huang
Zhuanpeng Chen
Jianchang Wei
Fang Wei
Jie Cao
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Gastric Cancer
Radiotherapy
Gastric Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08835-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model

Robust expression of LINE-1 retrotransposon encoded proteins in oral squamous cell carcinoma

Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer

A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer

Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer